ArticleWorld journal of oncology2026
Exploring the Association Between Colorectal Cancer Metastasis and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Analysis.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic syndrome-associated conditions and malignancies frequently co-exist, influencing each other's progression, severity, and prognosis. This study evaluates whether metabolic dysfunction-associated steatotic liver disease (MASLD) contributes to an increased risk of colorectal cancer (CRC) metastasis and in-hospital mortality using a large nationally representative database. Methods: We analyzed data from the National Inpatient Sample (NIS) database (2016 to 2020), identifying adult hospitalizations with CRC and then stratified the total population by the presence or absence of MASLD. Outcomes assessed included total CRC metastases, site-specific metastasis (such as gastrointestinal (GI) metastasis, liver metastasis, non-GI metastasis, lymphoid metastasis), and in-hospital mortality. Multivariate logistic regression model was used to adjust for patient demographics, comorbidities, and hospital characteristics. A subgroup analysis was performed to assess the association of MASLD and liver metastasis due to differences in sex, age, and race. Results: Among 814,270 hospitalizations with CRC, 35,595 (4.4%) had concurrent MASLD diagnosis. Hospitalizations with MASLD had a significantly higher prevalence of total metastasis (47.9% vs. 42.2%), liver metastasis (30.5% vs. 23.8%), GI metastasis (12.8% vs. 11.8%), and lymphoid metastasis (11.9% vs. 10.6%). Multivariate analysis also showed that MASLD was independently associated with higher odds of liver metastasis (adjusted odds ratio (aOR) 1.38, 95% confidence interval (CI) 1.31-1.46), total metastasis (aOR 1.24, 95% CI 1.18-1.30), GI metastasis (aOR 1.08, 95% CI 1.00-1.16), and lymphoid metastasis (aOR 1.12, 95% CI 1.04-1.21). Analysis also revealed an increased odds of in-hospital mortality (aOR 1.85, 95% CI 1.68-2.03) among hospitalizations with MASLD. The association of MASLD with liver metastasis was consistent across sex, age, and race. Conclusion: MASLD is significantly associated with metastatic CRC, especially liver metastasis, and increased in-hospital mortality. These findings support the need for increased surveillance and effective treatment for concurrent MASLD in patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.